Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7060893 | 0.90 | LIPG (0.33) | — | |
| SCHEMBL2526583 | 0.89 | LIPG (0.39) | — | |
| SCHEMBL1379817 | 0.86 | GABRA1 (0.38) | DAOHTR1A | |
| SCHEMBL4737660 | 0.79 | — | — | |
| SCHEMBL638188 | 0.79 | MEN1 (0.37) | — | |
| SCHEMBL7213697 | 0.79 | — | — | |
| SCHEMBL7616893 | 0.78 | GABRA1 (0.43) | — | |
| SCHEMBL10767160 | 0.77 | HIF1A (0.34) | HTR1A | |
| SCHEMBL8474445 | 0.76 | — | — | |
| SCHEMBL1079894 | 0.75 | GABRA1 (0.40) | ADRA2BADRA2CADRA2AHTR1ANISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2756007-A1 | PROCESS FOR ALKANE OLIGOMERIZATION | Rutgers, the State University of New Jersey (US) | 2014-07-23 | — | — | EP | claimed |
| WO-2013040262-A1 | PROCESS FOR ALKANE OLIGOMERIZATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-03-21 | — | — | WO | claimed |
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2011-07-28 | — | — | US | disclosed |
| EP-2318400-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010013037-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-02-04 | — | — | WO | disclosed |
| EP-1232166-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | Pharmasset Limited (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001034618-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | PHARMASSET LIMITED (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | SHH, SMO, GLI1 | DAO 4509/4885ADRA2B 2159/4885ADRA2C 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.